Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.
about
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsDNA methylation biomarkers: cancer and beyondDownregulation of RUNX3 and TES by hypermethylation in glioblastoma.Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas.The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Expression and aberrant promoter methylation of Wnt inhibitory factor-1 in human astrocytomasDrug resistance in cancer: an overview.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRO6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experienceMGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.New (alternative) temozolomide regimens for the treatment of glioma.Epigenetic changes in gliomas.Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.The good, the bad and the ugly: epigenetic mechanisms in glioblastoma.The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis.Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.An update on the epigenetics of glioblastomas.Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment.MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.O⁶-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas.Treatment of glioblastoma with herbal medicines.MicroRNA-142-3p is involved in regulation of MGMT expression in glioblastoma cells.Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma.Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.
P2860
Q24607903-3F079508-36EC-41BB-8FA0-68C73E502566Q26996421-49D2732F-FD4B-4EA4-9FB2-822063F747CFQ33253913-21A562CC-D695-4772-B177-E45C7F466CB5Q33381892-5F89E81D-AF77-49C1-B440-4E5C39DF56B1Q33578787-9E8DD1BD-7DBE-4CFB-8FA1-C8B986DDAEEAQ33777301-CE6E0965-C7F3-4A32-A21C-896AD1DC1130Q34437369-463F7A9A-AAE3-4524-BF46-AEE3D673B8C1Q34478948-5765B56B-F7DC-4C99-BFBF-F2536DBE12F3Q35001754-F3804875-8743-42DC-892A-29CFB46CB357Q35850389-D85E4859-BD13-4F4A-A665-F5B0B36E911FQ36096925-29C19808-D6CC-4459-9469-536D40832B63Q36177641-DABC8DB9-9C69-43F8-A50E-C698249825D6Q36552798-1272F83F-E693-4145-922C-01478B4DBD21Q37261125-E6562527-DB7A-4942-B638-C1ABB42C0AC0Q37287032-322ABEB8-168D-4331-9A43-5BA52E5C147FQ37344947-A50A2717-D189-42D1-9F0F-4C007145A936Q38024560-0195A466-0A95-422E-A354-CC5E13A510C6Q38326253-314794A0-0394-4B58-B547-1232C601D6F4Q38471533-15E5D52E-D52E-4A5A-BAE7-F19E38106FEDQ38491783-D43B11B5-C811-4128-BC96-8F3B27617974Q38686763-A7131DE4-EF84-4DA8-A60F-BC1A800DF3F8Q38944047-6FDBDFDF-3B5A-47F7-8529-ADBE16CB618FQ40102545-E858B03E-40DB-452B-8E4E-352B55D52D93Q44273844-7A7B164C-75E7-4D6D-8428-235B888B9849Q46614113-C535FA60-1BC5-4B5F-8D92-E342021AA9D3Q48162016-F8EAE8E3-04A1-4799-9F92-38BC45A0B8E3Q48986629-89B6C349-3C4B-485A-9981-0C8F826480F8Q50057784-9F685BCD-EBAB-4BDA-8A95-7685E1C99607Q52562698-05ABE8F6-73B7-44C7-8140-F571D55ADEBEQ55052526-671A6F9B-6E24-418D-B71C-B586C7845D1CQ55451515-265C1A21-BD68-4F39-83FE-7A6587973788Q55463316-BA568F48-038A-4100-9A05-668CE3EBD174Q55463506-896D3990-7991-4EEC-8D09-452469672EC4
P2860
Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Correlation of clinical featur ...... ene promoter in glioblastomas.
@en
Correlation of clinical featur ...... ene promoter in glioblastomas.
@nl
type
label
Correlation of clinical featur ...... ene promoter in glioblastomas.
@en
Correlation of clinical featur ...... ene promoter in glioblastomas.
@nl
prefLabel
Correlation of clinical featur ...... ene promoter in glioblastomas.
@en
Correlation of clinical featur ...... ene promoter in glioblastomas.
@nl
P2093
P1476
Correlation of clinical featur ...... ene promoter in glioblastomas.
@en
P2093
B Bataille
C J Larsen
F Lapierre
L Karayan-Tapon
T Chantereau
P304
P356
10.1023/B:NEON.0000033385.37098.85
P577
2004-07-01T00:00:00Z
P6179
1013082185